The nonsense-mediated mRNA decay (NMD) pathway functions not only to degrade transcripts containing premature termination codons (PTC), but also to regulate the transcriptome. UPF3B and RBM8A, important components of NMD, have been implicated in various forms of intellectual disability (ID) and Thrombocytopenia with Absent Radius (TAR) syndrome, which is also associated with ID. To gauge the contribution of other NMD factors to ID, we performed a comprehensive search for copy number variants (CNVs) of 18 NMD genes among individuals with ID and/or congenital anomalies. We identified 11 cases with heterozygous deletions of the genomic region encompassing UPF2, which encodes for a direct interacting protein of UPF3B. Using RNA-Seq, we showed that the genome-wide consequence of reduced expression of UPF2 is similar to that seen in patients with UPF3B mutations. Out of the 1009 genes found deregulated in patients with UPF2 deletions by at least 2-fold, majority (95%) were deregulated similarly in patients with UPF3B mutations. This supports the major role of deletion of UPF2 in ID. Furthermore, we found that four other NMD genes, UPF3A, SMG6, EIF4A3 and RNPS1 are frequently deleted and/or duplicated in the patients. We postulate that dosage imbalances of these NMD genes are likely to be the causes or act as predisposing factors for neuro-developmental disorders. Our findings further emphasize the importance of NMD pathway(s) in learning and memory.
INTRODUCTION
ID is a broad term encompassing a clinically and genetically highly heterogeneous group of disorders characterized primarily by impaired learning and memory (1) . ID affects as much as 3% of the population of resource rich countries and represents a major health burden (1) . ID can be caused by point mutations, translocations, and structural variations, which contribute to 10-20% of cases (2) . Recently, it has been shown that many ID genes encode for members of interacting proteins belonging to a small number of molecular networks, suggesting that many ID conditions share common underlying etiology (3, 4) .
Two members of the NMD pathway, UPF3B and RBM8A, have been linked to ID. Complete loss of function mutations in UPF3B (Mendelian Inheritance in Man, MIM 300298), an X-linked gene, cause various forms of ID, autism, schizophrenia and attention deficit hyperactivity disorder (MIM 300676) † Current address: Paw Print Genetics, Genetic Veterinary Sciences, Inc., Spokane, WA 99202, USA * To whom correspondence should be addressed at: Neurogenetics Laboratory, The University of Adelaide at the Women's and Children's Hospital, 72 King William Road, North Adelaide, South Australia 5006, Australia. Tel: +61 8 8161 6339; Fax: + 61 8 8161 7342; Email: jozef.gecz@adelaide. edu.au (5) . Inter-as well as intra-familial variability in clinical expressivity is emerging as one of the main features of the loss of UPF3B function (5, 6) . More recently, TAR syndrome (MIM 274000), has been described to be due primarily to compound heterozygous null (deletion) mutation and a regulatory single nucleotide polymorphism (SNP) of the RBM8A gene (MIM 605313) (7) . About 7% of TAR cases are associated with ID in which cerebral dysgenesis might be the underlying cause (8) . Micro-deletions and micro-duplications of the proximal 1q21.1 region, which contains RBM8A, are also frequently associated with ID, brain malformations and congenital anomalies without hallmarks of the TAR syndrome (8) .
NMD functions to degrade transcripts containing PTCs and to regulate the transcriptome. In metazoan, the UPF3B protein is associated with the exon junction complex (EJC), which contains RBM8A and is deposited at the exon-exon junctions of the mRNA during splicing. When the EJC bound mRNA is exported to the cytoplasm, it acquires UPF2 (MIM 605529) via direct interaction with UPF3B. In the pioneer round of translation, if there is a PTC upstream of the last EJC, the ribosome stalls at the PTC; this triggers the formation of downstream complexes, which includes UPF1 (MIM 601430), and recruits exo-and endonucleases to degrade the PTC containing transcript. NMD acts to ensure that potentially deleterious truncated proteins are not made from erroneous transcription (9) .
Strong evidence also supports a major role of NMD in regulating the expression of normal transcripts. Up to 5% of the transcriptome was reported to be deregulated in HeLa cell line depleted of UPF1, UPF2 or UPF3 proteins (10-13) and in lymphoblastoid cell lines (LCLs) of patients with complete loss of function mutations in UPF3B (14) . Among the deregulated genes, direct physiological targets of NMD were suggested to contain general features that may introduce a stop codon into the open reading frame in a context that is sufficient to initiate NMD (15) . These features include alternative splicing that causes frameshift and introduces PTC (16, 17) , upstream open reading frame (18) , intron in the 3' untranslated region (19) , leaky translation due to differential usage of internal ribosomal entry sites (20) , amino acid encoding for selenium (21) and long 3' untranslated region (22) . It is thought that NMD acts to regulate expression of the transcripts necessary for cellular biogenesis in a tissue dependent and temporal specific manner (23, 24) .
The function and development of the brain is particularly sensitive to dosage of NMD and EJC factors. Perhaps the most significant supporting evidence comes from the aforementioned patients with UPF3B mutations, and to a lesser extent, TAR patients carrying mutations in RBM8A and those with micro-duplications and deletions of the 1q21.1 proximal region. Many of the genes found deregulated in lymphoblastoid cell lines (LCLs) of patients with UPF3B mutations have important neuronal functions (14) . It has been reported that UPF3A, a protein paralog of UPF3B, was stabilized in the patients with loss of UPF3B function and able to rescue some NMD function. Importantly, high level of UPF3A was suggested to reduce the severity of the neurological phenotypes associated with loss of UPF3B (12, 14) . Studies using animal models have shown that depletion of NMD and EJC factors resulted in brain malformation or early embryonic lethality. In fruit flies, deletion of NMD genes smg1, upf2 or smg6 disrupted the formation of the neuromuscular junction synapse structure, reduced neurotransmission responses, and reduced synaptic vesicle cycling (25) . In zebrafish, down regulating either one of these three genes resulted in aberrant eye and brain patterning and substantial increase in faulty somitogenesis and mortality rates (26) . Haploinsufficiency of Magoh, an EJC component, caused microcephaly in mice (27) . Depletion of the EJC factor eIF4A3 enhanced the synaptic strength of neurons in rat (28) . Targeted disruption of either of Upf1 or Upf2 leads to embryonic lethality in mice (29, 30) . Taken together, it is plausible that mutations in other NMD members in man could result in ID and other overlapping clinical features as found in patients with mutations in UPF3B and RBM8A.
In this study, we investigated the contribution of CNVs encompassing 18 known NMD and EJC genes (31, 32) in a large cohort of patients with various neuro-developmental disorders. We identified CNVs encompassing UPF2, UPF3A (MIM 605530), SMG6 (MIM 610963), EIF4A3 (MIM 608546) and RNPS1 (MIM 606447), to be highly associated with these conditions. Using RNA-Seq, we provide further evidence that NMD is compromised in LCLs of patients with UPF2 deletions in a similar manner to that of patients with UPF3B mutations. This overlapping expression profile implicates CNVs of UPF2 in disease pathology and also points to a common molecular mechanism of NMD gene associated neuro-developmental disorders.
RESULTS

Enrichment of CNVs encompassing NMD and EJC factors in patients with neuro-developmental disorders
We assessed CNVs encompassing 18 known NMD and EJC genes to ID. To achieve this, we mined available CNV data in 57 356 patients with neuro-developmental disorders and 20 474 controls in large collated databases (see Materials and Methods; Supplementary Material, Table S1 and S2). We found that copy number losses of UPF2 (n ¼ 11), UPF3A (n ¼ 40), RBM8A (n ¼ 50) and copy number gains of UPF2 (n ¼ 13), SMG6 (n ¼ 31), RBM8A (n ¼ 101), EIF4A3 (n ¼ 22) and RNPS1 (n ¼ 25) were significantly enriched in the patient cohort (P , 0.05 by Fisher's exact test, Table 1 ). In 89 cases where the mode of inheritance could be tested, the CNVs were mostly de novo (54 cases) or were transmitted from an apparently normal parent (35 cases) (Supplementary Material, Table S3 ). The CNVs were variable in size and contained other genes, which could also contribute to the patients' phenotypes. Patients carrying these CNVs presented with various clinical phenotypes which all included ID, brain malformations and/or developmental anomalies. CNVs encompassing SMG5 (MIM 610962, 9 gains), SMG6 (23 losses), SMG7 (MIM 610964, 4 gains, 9 loses) SMG8 (MIM 613175, 11 gains, 2 losses), SMG9 (MIM 613176, 3 gains, 3 losses), MAGOH (MIM 602603, 2 gains, 2 losses), and CASC3 (MIM 606504, 1 gain, 1 loss) were also more frequently observed in the patients than controls; however, these differences were not statistically significant (Table 1 ). Our findings suggested that both duplications and deletions of NMD and EJC factor genes could contribute to disease pathology.
Deletions of UPF2 result in reduced UPF2 expression
To investigate the molecular consequences of at least some CNVs identified, we examined the effects of heterozygous deletions of UPF2. Eight females and three males with UPF2 deletions showed developmental delay with various dysmorphic features, speech and language problems, and deafness (Supplementary Material, Table S3 ). In 5 of these 11 deletions, where the inheritance could be tested, the deletions were de novo. UPF2 deletions were not seen in controls (Table 1) . Three of the deletion cases DGDP061, DGDP151, and DGAP195 are described in greater detail in the Supplementary clinical information and pictured in Figure 1 . We did not detect any mutation by Sanger sequencing on the remaining UPF2 allele in these three cases, suggesting UPF2 function was likely to be partially compromised. The minimal overlapping region deleted in all 11 UPF2 patients was 234 kb. This region contains full coding region of C10ORF47, part of the coding region of ECHDC3, and UPF2 ( Fig. 2A) . The functions of the C10ORF47 or ECHDC3 genes have not yet been determined, however they have been excluded because neither gene is expressed in the brain as investigated by RNA-Seq (BrainSpan: Atlas of the Developing Human Brain, http://developinghumanbrain.org).
We postulated at least three reasons why the UPF2 gene is likely involved in ID: i) UPF2 is ubiquitously expressed in all tissues including the brain (33) ; ii) UPF2 acts as a bridge between UPF3B (known to cause ID, see reference (5)) and the main NMD protein complex (34) ; and iii) UPF2 is essential for NMD function and cell development as demonstrated by both in-vitro and in-vivo experiments (10, 30, 35, 36) . In lymphoblastoid cell lines (LCLs) derived from two patients with UPF2 deletions (DGAP195 and GM06936) whom we could get access to, the UPF2 mRNA levels were at 50% (Fig. 2B ), while the UPF2 protein levels were at 50-75% with respect to the controls (Fig. 2C ).
Transcriptome-wide effects of reduced UPF2 expression
We hypothesized that loss of one allele of UPF2 would compromise NMD function similarly to the UPF3B mutations (5, 14) . We sequenced polyA+ RNA extracted from LCLs of patients with UPF2 deletions (n ¼ 2) using RNA-Seq (Illumina GAII) (Fig. 3A) . We generated 10 to 20 million reads per sample. We aligned the reads to the human genome (HG19) with CASAVA V1.6 (Illumina) and calculated gene expression as Reads Per Kilobase per Million mapped reads (RPKM) as previously described (14, 37) . Since the patients with UPF2 deletions are females and the controls and patients with UPF3B mutations used in subsequent comparisons are males, we excluded from the analysis all sex specific genes such as Xist and Y-linked genes; we also excluded genes known to be differently expressed between sexes in LCLs (38) . Compared to the controls (n ¼ 2), we identified 1009 differently expressed genes (DEGs) which were deregulated by at least 2-fold in the patients with UPF2 deletions (40% of which were down regulated, 60% were upregulated; Supplementary Material, Table S4 ). This represents 10% of all expressed genes in LCL (expression threshold RPKM . 3). Thirty-eight percent of these DEGs (379 genes) overlapped with the DEGs deregulated also by 2-fold in the patients with UPF3B mutations using the same platform (RNA-Seq) and assessed against the same controls (Fig. 3A) (14) . More importantly, ninety-five percent of Fig. 3B and C, respectively).
To test whether the association in gene expression changes in patients with UPF2 deletion and UPF3B mutations was random, we permutated lists containing a similar number of genes to the reported DEGs in the two patient groups. We then calculated the Pearson's correlation efficiency of gene expression differences, or fold changes with respect to the controls, between these two patient groups for each simulation (Supplementary Material, Fig. S1 ). After 100 simulations, the resulted R values (maximum 0.64, minimum 0.39 and average values 0.52) were much lower than the observed R values (0.79 and 0.77, Fig. 3B and C) , suggesting that the observed correlation was true.
We selected 13 genes for further validation using reversetranscribed quantitative real time PCR (RT-qPCR). Half of these genes were randomly selected, while the other half was chosen because they have been reported to be upregulated in patients with UPF3B mutations (5, 14) . To test for reproducibility of the RNA-Seq results, we used RNAs extracted from different and extended sets of LCLs from the patients and controls (Fig. 4A) . We showed that the majority of these genes (11 out of 13), including GADD45B and ARHGAP24 isoform 1, which are known to be upregulated upon inhibition of NMD (5, 11), were similarly upregulated in both patient groups. Subsequently, we selected 3 genes ROBO1, HNF1B and SERINC2 for validation using protein analyses (Fig. 4B and  C) . All three genes were shown to be upregulated by RNA-Seq (Fig. 4A and Supplementary Materials, Table S4 ). Western blot analyses were not as sensitive as RNA-Seq, but overall we were able to validate the trend of upregulation of ROBO1 and SERINC2 in UPF2 and UPF3B patient groups with respect to the controls (Fig. 4C) . We could only validate the upregulation of HNF1B in UPF3B patient group, but not UPF2 patient group (Fig. 4C) . In this respect, the gene expression changes identified by RNA-Seq in our study broadly reflected the changes of these proteins. These results were in agreement with a recent study which demonstrated that RNA-Seq and proteomic analysis had better concordance (than microarray and proteomic analysis), wherein 75% of genes and proteins were identified to have similar trend of expression changes (39) . Taken together, our results led us to conclude that NMD was at least partially deficient in the patients with UPF2 deletions, and that the transcriptome-wide consequences of compromised NMD in the patients with UPF2 deletions and UPF3B mutations were very similar.
We hypothesized that the clinical presentations of ID in the patients with UPF2 and UPF3B alterations were similar as a consequence of shared deregulated genes with known neuronal functions. Using the Database for Annotation, Visualization and Integrated Discovery (DAVID) (40), we identified DEGs with known neuronal functions (Supplementary Material, Table S5 ). We only selected DEGs that were deregulated in both patient groups in the same trend, i.e. both up or down regulated, as identified by RNA-Seq (this study) and exon array from our previous study (14) . These DEGs represent the most consistently deregulated genes when NMD is compromised and might be considered a priority in follow up functional studies in neuronal cell lines.
DISCUSSION
We have identified CNVs encompassing five NMD factors to be significantly associated with neuro-developmental disorders. Clinical features of individuals with copy number loss leading to reduced expression of UPF2. Subject DGDP061 at 15 years; please note her mild facial dysmorphism and cupped ears, which were posteriorly rotated and slightly low set; she has clinodactyly of both 5 th fingers. Subject DGAP195 at 12 years; she has developmental delay, ADHD, learning disabilities, major depression, and sensory problems. Subject DGDP151 at 15 years; she has a generalized triangular shape to her face and thin downslanting palpebral fissures; patches of missing hair are seen below behind her ear due to her chronic hair picking (trichotillomania). These CNVs likely drive or contribute to these conditions, including three known syndromes: UPF3A/neural tube defects (41), SMG6/17p13.3 microduplication syndrome (MIM 613215) and RNPS1/16p13.3 duplication syndrome (MIM 613458); and two novel pathogenic regions involving UPF2, which lies outside the critical region of DiGeorge Syndrome 2 (MIM 601362), and EIF4A3 (Table 1) . Interestingly, four of these gene loci are close to the subtelomeric regions (except UPF3A which lies within this region), which are rich in repeats and prone to rearrangements. The breakpoints of CNVs encompassing these genes also appear to be frequently within these regions (UPF2 CNVs, 15 out of 24 events; EIF4A3 CNVs, 16 out of 22 events) (Supplementary Materials, Table S3 ). This may offer an explanation for the relatively high frequency of CNVs reported here. Indeed, it is estimated that cryptic subtelomeric rearrangements collectively contribute to up to 10% of all ID cases (42, 43) .
We further investigated the role of UPF2 deletion in ID using RNA-Seq. We show that loss of one allele of UPF2 resulted in deregulation of the transcriptome similarly to that of previously studied patients with ID and loss of UPF3B function (Fig. 3) . Generally, the extent of transcriptome-wide effect is higher in the patients with single UPF2 allele deletions than in those with UPF3B mutations. This could be attributed to the fact that UPF2 also has a role in maintaining the telomere integrity (44) , and is involved in at least two branches of NMD, the classical NMD branch (11) and the UPF2/RNPS1 dependent branch (45) . Alternatively, this could also be due to an effect of other contiguously deleted gene(s) from the UPF2 region, or simply due to the small number of samples tested. Remarkably though, the expression profiles of the patients with single UPF2 allele deletions and UPF3B mutations were similar, pointing to a common molecular pathway, i.e. NMD, being deregulated (Fig. 3) . This also suggested that the deletion of a single UPF2 allele had significant effects to the overall deregulation of the transcriptome.
The patients with UPF2 deletions showed a broader phenotypic spectrum than those with UPF3B mutations. The hallmarks of the UPF2 deletion associated phenotypes include significant speech delay, hearing impairment, joint contractures and reduction deformity of legs (no digits) (Supplementary Material, Table S3 ). The differences in clinical consequences of UPF3B and UPF2 mutations may also be due to the fact that unlike for UPF3B, where the autosomal UPF3A paralog (B) RT-qPCR expression of UPF2 mRNA in the patients (n ¼ 2) and controls (n ¼ 5). Expression was measured using relative standard curve method and normalized against ACTB mRNA expression in the same sample. Results are representative of two independent experiments with the same results.
* P , 0.05 by Student's two-tailed t-test. (C) Western blot analysis of UPF2. Top panels: protein lysates from two patients and four controls are shown. Lysates from control 1 was loaded in decreasing amount in lanes 1-4 (100%, 75%, 50% and 25%, respectively) for comparison. Lysates from all other lanes were loaded as 100%. UPF2 expression is variable in the controls and is at 50-75% of normal level in the patients. a-Tubulin was used as loading control. These blots are representative of two independent experiments with similar results. Bottom panel: respective densitometry count showing relative UPF2 protein level in each sample. Densitometry (+SD) was performed directly on the images captured at low exposure time points.
is able to rescue the loss of UPF3B-NMD function (14) , there is no UPF2 paralog in human or other species. Interestingly, the mouse model with heterozygous deletion of Upf2 is phenotypically normal with no apparent neuronal or learning and memory deficits (30) (Bo Porse, personal communication). In this respect, it is also important to note that the majority of NMD targets do not seem to be conserved between human and the Upf2 knock out mouse tissues (14) . This adds additional complexity when studying NMD across species.
We validated the association of CNVs encompassing RBM8A (both gains and losses) with neuro-developmental disorders in this study using an expanded cohort of patients and a different cohort of controls with regard to the previous report (8) ( Table 1 ). There are some overlapping clinical features in these patients with TAR syndrome, including thinning of the corpus callosum and cysts (Supplementary Material, Table S3 ). RBM8A and other EJC constituents are in fact dispensable for NMD function. In fruit flies and nematodes, NMD does not require EJC (46) (47) (48) (49) . In man, NMD branch independent of the EJC factors RBM8A, MAGOH, CASC3 and EIF4A3 has also been described (45) , although this branch was thought to be a minor NMD branch (50) . Perhaps this is why partial loss of RBM8A may only act as a pre-disposing factor and requires a second hit (the regulatory SNP) for fully manifested TAR syndrome.
Copy number gains of UPF2, SMG6, RBM8A, EIF4A3 and RNPS1 were significantly enriched in ID patients (Table 1) . This suggests that enhancement of NMD function may also be deleterious for normal neuronal development and function. In fact, overexpression of the NMD gene SMG1 enhanced UPF1 phosphorylation and accelerated the decay rate of target transcripts (51) ; and the varying amount of RNPS1 in different HeLa strains has been shown to affect NMD efficiency (52). However, increasing gene dosage may not necessarily lead to enhanced NMD function, since limiting proteins in protein complexes may be titrated out by the over expressed factors, resulting in attenuation of NMD. Specifically, overexpression of upf1 in yeast abolished the requirement for upf2, indicating that high level of upf1 is sufficient to maintain NMD in the active state (53) . In HeLa cells, NMD efficiency was enhanced upon over expression of SMG5, SMG6 and SMG7, but not UPF1, UPF2, UPF3A, UPF3B and SMG7 (23) . Notably, the genes deregulated in HeLa cells depleted of NMD factors UPF1, UPF2 or UPF3 did not overlap much with those reported in LCLs of patients with UPF3B mutations (14) . As such, the consequences of copy number gains of NMD and EJC factors in LCLs might be different and require further investigation. Taken together, our results suggest that CNVs encompassing NMD and EJC factor genes affect NMD function and result in a range of neurodevelopmental clinical presentations.
CNVs of some of the NMD gene loci were also found in apparently normal controls, but at a much lower frequency (Table 1) . In some cases, the NMD CNVs were inherited from an apparently normal parent (Supplementary Material,  Table S3 ), which is not unusual (54) . However, the explanations for this apparent 'non-penetrance' may lie in the extent of individual's innate NMD efficiency, which may not go below the 'clinically relevant' threshold. Cumulative evidence points towards considerably variable NMD efficiency in the populations, which could be influenced by expression quantitative trait loci (55), competitive pathway (56) and feedback regulation (23, 57) . It is also possible that some CNVs are simply non-pathogenic. Larger datasets and further investigations are required to address this complexity. Our results also demonstrate that NMD efficiency can be influenced by copy numbers as well as point mutations in the NMD and EJC genes. Such genetic variations can help to explain variable NMD efficiency which has been shown to modulate not only the phenotypic outcomes of genetic disorders involving NMD (58) (59) (60) , but also patients' response to PTC read-through drugs (61) .
Our work demonstrates a broader than expected involvement of NMD in normal brain development and function. We hope it will trigger future investigations into the role of NMD genes in a broad spectrum of neuro-developmental and other congenital disorders. Better understanding of the inter-individual NMD variation will also help to interpret the complexity of the human phenotype.
MATERIALS AND METHODS
CNV screening methodology by the Signature Genomics Laboratory
From March 2004 through November 2010, 45 744 probands were referred to the Signature Genomic Laboratories for clinical aCGH testing, with the most common clinical presentations being ID, developmental delay, and/or multiple congenital anomalies. Patients' DNAs were subjected to aCGH using either bacterial artificial chromosome (BAC) microarray (Signature Chip) or a whole genome oligonucleotide-based microarray (SignatureChip Oligo Solution). All abnormalities detected by aCGH were visualized by metaphase or interphase fluorescence in situ hybridization (FISH) using one or more BAC clones determined to be in the abnormal region by aCGH (62) . The six versions of the BAC microarray had increasing coverage of the genome, and the array version used depended on the date of sample submission. Values were normalized to ACTB mRNA level in the same samples using a relative standard curve method and converted into fold change. Results are averaged from two independent RT-qPCRs. Table S6 contains the sequences of all primers used in this study. (B) Western blot analysis of ROBO1, HNF1B and SERINC2, which were all reported to be upregulated in UPF2 and UPF3B patients by RNA-Seq. Expression of the proteins were detected using commercially available antibodies: ROBO1 (Santa Cruz, sc-25672), HNF1B (sc-7411) and SERINC2 (sc-138678). ACTB was used as a loading control. Image at low exposure time points were captured directly from the membrane using camera-based quantitative biomolecular imager (ImageQuant LAS 4000, Fujifilm). The blots shown are representative of two independent experiments. (C) Densitometry analysis of the western blots. Densitometry (+SD) was performed on images shown in (B) at two low exposure time points using Multi Gauge V.3 (Fujifilm). Values were normalized against signal obtained from ACTB bands from the same blot, and normalized against the controls to convert to fold change.
of the genome and were used to test 15 Table S1 ) and The Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources (DECIPHER, 11 247 cases). These databases contain high quality curated genome-wide CNV information obtained from diagnostic cases. To assess the frequency of these NMD CNVs in controls, we extracted data from the Database of Genomic Variants (DGV) (66) . Due to redundancy of the representation of the HapMap samples, we counted the controls in only one study as representative (67) (68) (69) (70) (71) . The total number of controls accounted for in DGV was 12,145. To increase the number of controls for comparison, we used CNV information from a recently published dataset of 8,329 cases (72) . In total, we have surveyed CNVs encompassing known NMD and EJC genes in 57 356 patients and 20 474 controls (Table 1; Supplementary  Material, Table S2 ).
General methods
Maintaining LCLs, RNA extraction, RT-PCR, RT-qPCR and western blot were performed using protocols previously described (14) .
RNA-Seq analysis
Approximately twenty mg of RNA was processed and sequenced by GeneWorks (Australia) on the Illumina GAII platform. Reads were aligned by CASAVA v1.6 using the exact same protocols as previously described (14) . Raw and processed RNA-Seq data have been deposited to the Gene Expression Omnibus repository under accession number GSE35420.
Statistical analysis
Where appropriate, Student's t-test, Fisher's exact test or Pearson's correlation test was employed to aid analysis when comparing difference between two groups.
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